MarginsXMarginsX
Home › Markets › Health Care › ANIX

Anixa Biosciences Inc. (ANIX)

ANIX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.55
-2.67% on the day
Market cap
$88.6M
Micro cap
Revenue · 2024
$210K
0.0% on 2023
Net income · 2024
-$12.6M
-5978.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-10-31, https://www.sec.gov/Archives/edgar/data/715446/000149315225001787/0001493152-25-001787-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-10-31.

Profile

FieldValue
TickerANIX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000715446

Financials · 2024

LineValue
Revenue$210K
Net income-$12.6M
Operating income-$13.8M
Net margin-5978.1%
Operating margin-6586.2%
Revenue growth0.0%
Cash$1.3M
Total assets$21.6M
P/E (computed)Net income was not positive
P/S (computed)422.1×

Warning signs

Cash runway
2.3 months
$1.4M cash at July 31, 2026
Share count, 1 year
+5.6%
2025-09-10 to 2026-09-09 · +11.9% over 3 years
Going-concern doubt
No
10-Q filed September 9, 2026
Insider net buying, 12 months
$460K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-09-09
Cash and burn$1.4M cash; operating cash flow -$1.8M a quarter.Report 2026-07-31
Shares outstanding34,763,802 (2026-09-09); 32,916,915 a year earlier; 31,070,022 three years earlier.Cover page 2026-09-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorHaskell & White LLP, Irvine, California, United StatesPCAOB Form AP 2026-02-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $460K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-07-31
Not filed-$2.6M-$1.8M$1.4MNo debt tagsNeeds four quarters10-Q 2026-09-09
Q2 2026
2026-04-30
Not filed-$2.5M-$1.7M$1.5MNo debt tagsNeeds four quarters10-Q 2026-06-10
Q1 2026
2026-01-31
Not filed-$2.6M-$2.6M$1.5MNo debt tagsNeeds four quarters10-Q 2026-03-09
Q4 2025
2025-10-31
Not filed-$2.7M-$1.3M$1.2MNo debt tagsNeeds four quarters10-K 2026-01-12
Q3 2025
2025-07-31
Not filed-$2.3M-$1.5M$1.5MNo debt tagsNeeds four quarters10-Q 2026-09-09
Q2 2025
2025-04-30
Not filed-$2.8M-$1.5M$1.9MNo debt tagsNeeds four quarters10-Q 2026-06-10
Q1 2025
2025-01-31
Not filed-$3.2M-$2.9M$1.1MNo debt tagsNeeds four quarters10-Q 2026-03-09
Q4 2024
2024-10-31
Not filed-$2.9M-$927K$1.3MNo debt tags$210K10-K 2026-01-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-17.6%
1 month-1.9%
3 months-18.1%
Year to date-16.0%
1 year-40.3%
From 52-week high-49.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
GNLXGenelux Corporation$1.92+2.95%$86.9M
NKTXNkarta Inc.$1.21+1.68%$86.8M
RLYBRallybio Corporation$15.43-1.88%$86.4M
NBPNovaBridge Biosciences$0.7915-6.87%$91.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier